Read the latest press releases from Calliditas Therapeutics by clicking on a title below.

For press enquiries please contact us.

Calliditas strengthens its US Commercial and Medical Affairs Organization

Calliditas Therapeutics to Host Key Opinion Leader Perspectives Webinar on the Pathophysiology and Treatment of IgA Nephropathy in Clinical Practice

First Patient Dosed in NefIgArd Open Label Extension Study

Calliditas Announces Full Enrollment of the Phase 3 NefIgArd Trial

Positive Phase 1 results in high-dose setanaxib trial

Agenda for Calliditas virtual R&D Day on January 20, 2021

Calliditas Therapeutics AB
Kungsbron 1, C8
SE-111 22 Stockholm
Sweden

Company number: 556659-9766

© Calliditas Therapeutics AB 2021